ARA-290, also called cibinetide, is an eleven amino acid peptide that copies one exposed face of erythropoietin rather than the whole hormone, and the tissue protection reported for it is explained by a proposed second receptor rather than by any blood-forming activity. That receptor, called the innate repair receptor, is described as an erythropoietin receptor subunit paired with the beta common subunit CD131, assembled locally in injured tissue rather than standing ready in healthy tissue. The functional pharmacology is reproducible across laboratories, the molecular identity of the receptor remains disputed, and ARA-290 itself is investigational and approved by no major regulator.
ARA-290 is an eleven amino acid erythropoietin fragment whose reported tissue protection is attributed to a proposed EPOR and CD131 heterocomplex rather than to erythropoiesis, a model supported by knockout pharmacology but not yet confirmed by any published receptor structure.
The innate repair receptor is a functional label rather than a gene name, and that single point clears up most of the confusion around it. No locus encodes it; the name describes a complex that forms when the EPOR subunit associates with CD131, the beta common chain shared by the interleukin 3, interleukin 5 and granulocyte macrophage colony stimulating factor receptors. The classical erythropoietic receptor is structurally simpler, a homodimer of two identical EPOR chains on erythroid progenitors.
| Criterion | Classical erythropoietic receptor | Innate repair receptor (proposed) |
|---|---|---|
| Subunit composition | EPOR homodimer, two identical chains | EPOR paired with CD131, encoded by CSF2RB |
| Erythropoietin affinity | High | Substantially lower, described qualitatively, no published dissociation constants |
| Reported cellular carriers | Erythroid progenitors | Neurons, Schwann cells, corneal and retinal tissue, renal tubule, myocytes, endothelium |
| Functional output | Red cell production | Tissue protection reported in injury models |
The innate repair receptor is not a separate gene product but a proposed heterocomplex of the EPOR subunit with the CD131 beta common chain encoded by CSF2RB, distinct from the EPOR homodimer that drives red cell production.
Erythropoietin folds into a four helix bundle whose surfaces do different jobs, and the two interfaces that dock into the erythroid receptor are built mainly from helices A and D with their connecting loops. Helix B sits across the molecule with one face turned toward solvent, outside that binding interface entirely, and that aqueous exposed face is the region ARA-290 reproduces. The design logic is subtractive: copying only a surface the erythroid receptor does not read should preserve whatever contacts the protective complex makes while losing the ability to trigger red cell production.
ARA-290 reproduces the aqueous exposed face of helix B of erythropoietin as an eleven residue linear peptide, a surface that lies outside both binding sites used by the erythroid homodimer.
The reported signaling looks familiar to anyone who has read the erythropoietin literature, because the same proximal kinase is involved. Receptor engagement is described as bringing Janus kinase 2 molecules close enough to transphosphorylate, opening docking sites for signal transducer and activator of transcription proteins, with a parallel phosphoinositide 3 kinase and Akt arm carrying most of the survival signal. The different outcome is attributed to combinatorics rather than to a different kinase: CD131 replaces one EPOR tail, so the phosphotyrosine landscape and the adaptor recruitment differ, as do signal amplitude and duration.
Reported downstream signaling runs through Janus kinase 2 with STAT3 recruitment, a phosphoinositide 3 kinase and Akt survival arm raising Bcl-xL and Bcl-2, and suppression of nuclear factor kappa B driven cytokine transcription, mapped mainly in cultured cells with only indirect in vivo support.
Separating the two activities was the point of the program, and it grew out of a clinical failure. Trials giving erythropoietin for neuroprotection, most visibly in acute stroke, produced disappointing or harmful results, and the raised hematocrit, higher blood viscosity and thrombotic risk that follow red cell stimulation were widely blamed, particularly where the hormone was combined with thrombolysis. Removing erythropoietic activity became a design requirement rather than a bonus.
| Criterion | Erythropoietin | Carbamylated erythropoietin | ARA-290 |
|---|---|---|---|
| Erythroid receptor binding | High affinity at the homodimer | Lost through lysine carbamylation | Absent; copies a non-binding face |
| Hematologic effect reported | Raises hematocrit and blood viscosity | No erythropoiesis reported | Hemoglobin unchanged in the sarcoidosis trial |
| Molecule | Glycoprotein, roughly 30 kilodaltons, expressed | Modified glycoprotein, expressed | Eleven residues, synthesized |
| Plasma persistence | Hours | Hours | Minutes |
The published sarcoidosis trial reported hemoglobin essentially unchanged from baseline to the end of dosing with no significant difference between treated and placebo groups, the main empirical support for the absence of erythropoietic activity, though hematocrit, reticulocyte and platelet results were not broken out and the trials were small and short.
Conditionality is the feature that makes the model interesting and also the hardest part of it to verify. The complex is described as largely absent from healthy resting tissue and as assembling locally under metabolic stress, so the receptor is presented less as a standing feature of a cell than as a state a cell enters when it is in trouble. Reported inducing signals are hypoxia, ischemia and reperfusion, mechanical or toxic injury, and proinflammatory cytokines such as tumor necrosis factor alpha and interleukin 1 beta, with hypoxia inducible factor activity implicated in the transcriptional response.
The complex is reported to be largely absent from healthy tissue and to rise within hours of hypoxic, ischemic, toxic or cytokine-driven injury before subsiding as repair proceeds, although these expression maps rest largely on antibody based detection with a documented cross-reactivity problem and are best treated as provisional.
Tissue protection in this literature is an umbrella covering at least three separable effects, and keeping them apart matters when reading the claims. The distinction between prevention and repair is not merely semantic: most animal work dosed at or near the time of injury and therefore tests prevention, while the human neuropathy studies enrolled people with established nerve damage and ask the harder repair question.
The reported protection separates into three distinct effects, reduced apoptosis in ischemia models, lower tissue tumor necrosis factor alpha, interleukin 1 beta and interleukin 6 with a macrophage shift toward resolution, and small increases in corneal nerve fiber density in small phase 2 neuropathy trials.
The strongest evidence for the model is genetic rather than biochemical: in mice lacking the beta common receptor, the tissue protective effects of erythropoietin and of its non-erythropoietic derivatives are reported to be abolished while erythropoiesis remains intact. That functional dissociation is difficult to explain unless CD131 participates in the protective pathway. What has not followed is a matching molecular picture, and much of the foundational work traces to a concentrated group of investigators with commercial ties to the compound's development, which makes independent replication more important than usual.
The functional pharmacology is reproducible, with beta common receptor knockout abolishing tissue protection while leaving erythropoiesis intact, but the molecular identity of the receptor is unsettled, since no high resolution structure of an EPOR and CD131 complex has been published and much earlier immunodetection relied on antibodies later shown to bind unrelated proteins.
Careful language is not a formality here, because mechanism descriptions read persuasively and are easily mistaken for evidence of benefit. Describing how a molecule is proposed to work says nothing about whether it works: a mechanism can be internally coherent, supported by knockout data and consistent with cell biology, and still fail to produce a measurable benefit for patients, which is the ordinary outcome for compounds at this stage. In this case the mechanism is itself a research model whose central claim, the existence of a specific heteromeric receptor, is not fully resolved.
ARA-290, known in the clinical literature as cibinetide, is an investigational compound with no approval from the United States Food and Drug Administration, the European Medicines Agency or any comparable regulator, and human study has reached only phase 2 in a small number of conditions using patient reported and imaging surrogate endpoints rather than demonstrated clinical benefit.
Educational use only. This article describes what the published scientific and clinical literature reports about ARA-290. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
